{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:52:42Z","timestamp":1790617962032,"version":"4.1.0"},"reference-count":20,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The aim of this study was to evaluate the efficacy of a treat-and-extend (T&amp;E) regimen of ranibizumab as the first-choice treatment in macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). We conducted a retrospective study of 20 patients who developed MO due to BRVO treated with intravitreal ranibizumab in a T&amp;E regimen between 2016 and 2017 with a minimum follow-up of two years. Patients were classified as complete responders if treated with ranibizumab alone or incomplete responders if salvage treatment with other medications or laser was needed. Data on best corrected visual acuity (BCVA) and central macular thickness (CMT) every 6 months were recorded. The mean BCVA (logMAR) improved from 0.60 \u00b1 0.36 to 0.29 \u00b1 0.44 and the CMT decreased from 559.85 \u00b1 198.61 to 305.85 \u00b1 11.78 \u03bcm. We found statistically significant differences between complete and incomplete responders on the average number of injections during the second year (2.46 \u00b1 2.18 compared to 5.43 \u00b1 1.27; p = 0.007) and change of the BCVA and CMT between both groups (p &lt; 0.001) at 6, 12, 18 and 24 months. T&amp;E seems to be effective in MO secondary to BRVO, improving visual function and decreasing CMT, with less need for injections.<\/jats:p>","DOI":"10.3390\/ph15010059","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T20:21:56Z","timestamp":1641759716000},"page":"59","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-8163","authenticated-orcid":false,"given":"Carmen Ant\u00eda","family":"Rodr\u00edguez-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Ophthalmology Service, Complejo Hospitalario Universitario de Vigo, Estrada do Meixoeiro, s\/n, 36213 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Campo-Gesto","sequence":"additional","affiliation":[{"name":"Ophthalmology Service, Complejo Hospitalario Universitario de Vigo, Estrada do Meixoeiro, s\/n, 36213 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Complejo Hospitalario Universitario de Vigo, Cami\u00f1o Dos Ca\u00f1otais n 44, 36204 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Gayoso-Rey","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Complejo Hospitalario Universitario de Vigo, Cami\u00f1o Dos Ca\u00f1otais n 44, 36204 Vigo, Spain"},{"name":"Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Cami\u00f1o Dos Ca\u00f1otais n 44, 36204 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in Australia: The Blue Mountains Eye Study","volume":"114","author":"Mitchell","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The preva-lence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1055\/s-0042-123834","article-title":"Retinaler Venenverschluss\u2014Wann, womit und wie therapieren?","volume":"234","author":"Bajor","year":"2017","journal-title":"Klin. Mon. Augenheilkd."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","article-title":"Natural history of branch retinal vein occlusion: An evidence-based systematic review","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus ver-teporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"787","article-title":"Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: The Retain study","volume":"100","author":"Fajnkuchen","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ajo.2008.08.016","article-title":"Prospective study of intravitreal Ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion","volume":"147","author":"Spaide","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from Ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal Aflibercept for macular edema following branch retinal vein occlusion","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12325-017-0484-0","article-title":"The clinical effectiveness of ranibizumab treat and extend regimen in nAMD: Systematic review and network meta-analysis","volume":"34","author":"Danyliv","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_13","first-page":"39","article-title":"Results of a treat-and-extend regimen of intravitreal ranibizumab injection for macular edema due to branch retinal vein occlusion","volume":"72","author":"Hosogi","year":"2018","journal-title":"Acta Med. Okayama"},{"key":"ref_14","first-page":"517","article-title":"Two-year results of intravitreal ranibizumab injections using a treat-and-extend regimen for macular edema due to branch retinal vein occlusion","volume":"73","author":"Hosogi","year":"2019","journal-title":"Acta Med. Okayama"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Arai, Y., Takahashi, H., Inoda, S., Sakamoto, S., Tan, X., Inoue, Y., Tominaga, S., Kawashima, H., and Yanagi, Y. (2021). Efficacy of modified treat-and-extend regimen of Aflibercept for macular edema from branch retinal vein occlusion: 2-year prospective study outcomes. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143162"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00417-021-05150-y","article-title":"Prospective trial of treat-and-extend regimen with afliber-cept for branch retinal vein occlusion: 1-year results of the PLATON trial","volume":"259","author":"Park","year":"2021","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1055\/s-0042-122340","article-title":"Injektionsstrategien bei der Anwendung intravitrealer VEGF-Inhibitoren: \u201cPro Re Nata versus Treat and Extend\u201d","volume":"235","author":"Hufendiek","year":"2018","journal-title":"Klin. Mon. Augenheilkd."},{"key":"ref_18","first-page":"43","article-title":"Two-year follow-up results of patients with macular oedema due to retinal vein occlusion treated with Ranibizumab","volume":"73","year":"2017","journal-title":"Czech Slovak Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with Ranibizumab","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.2147\/OPTH.S314840","article-title":"The impact of non-ophthalmic factors on intravitreal injections during the COVID-19 lockdown","volume":"15","author":"Ashrafzadeh","year":"2021","journal-title":"Clin. Ophthalmol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/1\/59\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:26:50Z","timestamp":1760362010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/1\/59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ph15010059"],"URL":"https:\/\/doi.org\/10.3390\/ph15010059","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1186\/s40942-025-00703-3","asserted-by":"object"}]},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]}}}